JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in familial adenomatous polyposis. REC-4881’s addressable market is now broader than previously expected, creating blockbuster potential, the analyst tells investors in a research note. JPMorgan sees peak sales of over $1B and a 60% probability of success. In addition, Recursion’s REC-617, a CDK7 inhibitor, has shown early anti-tumor activity in platinum-resistant ovarian cancer, says JPMorgan.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating
- Cautious Hold Rating on Recursion Pharmaceuticals Amid Promising REC-4881 Data and Safety Concerns
- Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals
- Unusually active option classes on open December 8th
- Recursion Pharmaceuticals Reports Positive TUPELO Trial Results